Table 1.
Basic characteristics
| Characteristics | Value (%) |
|---|---|
| Total patients/LO number | 70/144 |
| Sex(male/female) | 37(52.9%)/33(47.1%) |
| Age (mean ± SD, years old) | 57.5 ± 7.6 |
| BMI (mean ± SD, mg/m2) | 24.6 ± 2.9 |
| Serum CEA (mean ± SD, ng/ml) | 28.7 ± 21.8 |
| Serum CEA stratification (≤ 15 ng/ml/ > 15 ng/ml) | 32(45.7%)/38(54.3%) |
| Primary tumor site (colon/rectum) | 34(48.6%)/36(51.4%) |
| Pathological classification (low/middle- high differentiated) | 28(40.0%)/42(60.0%) |
| TNM stage (stage I-III/stage IV) | 47(67.1%)/23(32.9%) |
| ECOG score (0/1) | 35(50.0%)/35(50.0%) |
| Number of LO per person(1/2/3/4/5 LO) | 26(37.1%)/21(30.0%)/17(24.3%)/5(7.1%)1(1.4%) |
| Mean number of LO per person ( mean ± SD) | 2.1 ± 1.0 |
| Number of LO stratification (≤ 2 / > 2 nodules) | 47(67.1%)/23(32.9%) |
| LO location (left/right lung) | 79(54.9%)/65(45.1%) |
| Mean GTV per LO ( mean ± SD, cm3) | 31.2 ± 18.1 |
| Cumulative GTV per person ( cm3) | 53.0 ± 22.4 |
| Cumulative GTV stratification (≤ 40 / > 40 cm3) | 31(44.3%)/39(55.7%) |
| D90 per LO (mean ± SD, Gy) | 116.4 ± 11.8 |
| Systemic treatments (C + TT/C alone) | 43(61.4%)/27(38.6%) |
| Progression disease (Yes/no) | 64(91.4%)/6(8.6%) |
| Disease-free interval (months) | 11.0 ± 6.9 |
| Disease-free interval stratification (≤ 12 / > 12 months) | 47(67.1%)/23(32.9%) |
| Disease progression type (local/regional/distance failure) | 9/22/61 |
| PFS (median, 95% CI) (months) | 10.0(95% CI: 8.9–11.1) |
| 6-, 12-, 24-month PFS rates (%) | 72.9%/32.9%/5.9% |
| OS (median, 95% CI) (months) | 30.8(95% CI: 27.1–34.4) |
| 1-, 2-, 3-year OS rates (%) | 95.7%/67.4%/42.5% |
LO Lung oligometastases, ECOG Eastern Cooperative Oncology Group, PFS progression free survival, OS overall survival, CEA Carcinoembryonic antigen, C Chemotherapy (capecitabine plus oxaliplatin), TT target therapy, GTV gross tumor volume